Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs VAC 3S (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors InnaVirVax
- 10 Jun 2017 Biomarkers information updated
- 16 Jun 2016 The primary endpoint timeframe has been changed from (Day 0 to week 48) to (Day 0 to week 16).
- 16 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.